{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:32:55Z","timestamp":1791639175259,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bmcl.2025.130193","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T08:45:08Z","timestamp":1742719508000},"page":"130193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Design, synthesis, and evaluation of a novel protein degrader FPFT-2216"],"prefix":"10.1016","volume":"123","author":[{"given":"Yasuyuki","family":"Ueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiteru","family":"Eikyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoshi","family":"Kunimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Kanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Izuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130193_bb0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmcl.2025.130193_bb0010","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2025.130193_bb0015","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/cancers15051558","article-title":"Novel agents as Main drivers for continued improvement in survival in multiple myeloma","volume":"15","author":"Puertas","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmcl.2025.130193_bb0020","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bmcl.2025.130193_bb0025","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s00277-024-05730-y","article-title":"Therapeutic progress in relapsed\/refractory multiple myeloma","volume":"103","author":"Chen","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bmcl.2025.130193_bb0030","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5","article-title":"Click chemistry: diverse chemical function from a few good reactions","volume":"40","author":"Kolb","year":"2001","journal-title":"Angew Chem Int Ed Eng"},{"key":"10.1016\/j.bmcl.2025.130193_rf0035","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1021\/cr0783479","article-title":"Cu-catalyzed azide-alkyne cycloaddition","volume":"108","author":"Meldal","year":"2008","journal-title":"Chem Rev"},{"key":"10.1016\/j.bmcl.2025.130193_rf0040","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1002\/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4","article-title":"A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective \u201cligation\u201d of azides and terminal alkynes","volume":"41","author":"Rostovtsev","year":"2002","journal-title":"Angew Chem Int Ed Eng"},{"key":"10.1016\/j.bmcl.2025.130193_rf0045","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1021\/jo011148j","article-title":"Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides","volume":"67","author":"Torn\u00f8e","year":"2002","journal-title":"J Organomet Chem"},{"key":"10.1016\/j.bmcl.2025.130193_rf0050","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1021\/ja021381e","article-title":"Bioconjugation by copper(I)-catalyzed azide-alkyne [3 + 2] cycloaddition","volume":"125","author":"Wang","year":"2003","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2025.130193_rf0055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1021\/ja0471525","article-title":"Copper(I)-catalyzed synthesis of azoles. DFT study predicts unprecedented reactivity and intermediates","volume":"127","author":"Himo","year":"2005","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2025.130193_bb0060","series-title":"Thiophene derivative and use thereof","author":"Watanabe","year":"2019"},{"key":"10.1016\/j.bmcl.2025.130193_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bmcl.2025.130193_bb0070","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M109.052647","article-title":"CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability","volume":"284","author":"Huart","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2025.130193_bb0075","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1084\/jem.20131033","article-title":"Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia","volume":"211","author":"J\u00e4r\u00e5s","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.bmcl.2025.130193_bb0080","year":"2023","journal-title":"JSH Pract Guidelines Hematol Malignancies"},{"key":"10.1016\/j.bmcl.2025.130193_bb0085","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","article-title":"IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos","volume":"132","author":"Fedele","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2025.130193_bb0090","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nsmb.2874","article-title":"Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs","volume":"21","author":"Chamberlain","year":"2014","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bmcl.2025.130193_bb0095","series-title":"Guidance for industry estimating the maximum safe starting dose in initial clinical trials for Therapeutics in adult healthy volunteers","article-title":"Monkey dose converted from mouse dose based on body surface area: 0.1 (mg\/kg)*3.1\/12.3\u22520.025 (mg\/kg)","author":"Human-equivalent dose (HED): A value calculated by converting the dose for test animals based on body surface area to the dose for humans","year":"2005"},{"key":"10.1016\/j.bmcl.2025.130193_bb0100","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2767-9764.CRC-23-0264","article-title":"FPFT-2216, a novel anti-lymphoma compound, induces simultaneous degradation of IKZF1\/3 and CK1\u03b1 to activate p53 and inhibit NF\u03baB signaling","volume":"4","author":"Kanaoka","year":"2024","journal-title":"Cancer Res Commun"}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:06:50Z","timestamp":1762344410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25001027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":20,"alternative-id":["S0960894X25001027"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130193","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and evaluation of a novel protein degrader FPFT-2216","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"130193"}}